The protein PprI provides protection against radiation injury in human and mouse cells

Abstract

Severe acute radiation injuries are both very lethal and exceptionally difficult to treat. Though the radioresistant bacterium D. radiodurans was first characterized in 1956, genes and proteins key to its radioprotection have not yet to be applied in radiation injury therapy for humans. In this work, we express the D. radiodurans protein PprI in Pichia pastoris yeast cells transfected with the designed vector plasmid pHBM905A-pprI. We then treat human umbilical endothelial vein cells and BALB/c mouse cells with the yeast-derived PprI and elucidate the radioprotective effects the protein provides upon gamma irradiation. We see that PprI significantly increases the survival rate, antioxidant viability, and DNA-repair capacity in irradiated cells and decreases concomitant apoptosis rates and counts of damage-indicative γH2AX foci. Furthermore, we find that PprI reduces mortality and enhances bone marrow cell clone formation and white blood cell and platelet counts in irradiated mice. PprI also seems to alleviate pathological injuries to multiple organs and improve antioxidant viability in some tissues. Our results thus suggest that PprI has crucial radioprotective effects on irradiated human and mouse cells.

Improving Biotransformation Efficiency of Arthrobacter simplex by Enhancement of Cell Stress Tolerance and Enzyme Activity

“…Impressively, the enhanced role of IrrE not only expands to other microorganisms, such as Escherichia coli, ,− Pseudomonas putida, P. aeruginosa, , Zymomonas mobilis, Lactococcus lactis, Saccharomyces cerevisiae, , but even in Brassica napus , and mammalian cells. − By in vitro random mutagenesis and in vivo selection, various IrrE variants have been obtained, which gave E. coli , or S.…”

Naturally-Derived PHA-L Protein Nanoparticle as a Radioprotector Through Activation of Toll-Like Receptor 5

“…At present, there is an unmet need to develop therapeutic agent against radiation enteropathy with good biocompatibility and efficacy. 60–63 Amifostine is an FDA-approved radioprotector used in clinical settings during radiotherapy. However, its short half-life in patients limits its efficacy and extensive clinical use.…”

Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection

“…Previous studies have revealed that several certain proteins were able to function as protectors against radiation damage. 680–682 Long et al designed phytohemagglutinin (PHA-L) protein NPs to activate toll-like receptor 5 (TLR5) for radioprotection. 683 Due to spontaneous biocompatibility, the PHA-L protein NPs showed no significant cytotoxicity to CHO-K1 cells at a concentration of 100 μg mL −1 .…”